CUROGEN

Expanding Possibilities

in Autoimmune Care

Our Purpose

Revolutionizing autoimmune care:
Restoring balance, renewing health.

Autoimmune diseases arise when the immune system mistakenly attacks the body, leading to chronic inflammation and severe complications. Despite advances in immunology, current treatments offer only partial relief. Many patients either do not respond to existing therapies or experience diminished efficacy over time due to the development of anti-drug antibodies. Our goal is to advance combination immunotherapies by developing innovative therapeutics that offer superior efficacy, enhanced durability, and significant long-term benefits for patients.

Our Mission

Through cutting-edge research and proprietary technologies, we aim to address the unmet needs of autoimmune disease patients and restore immune balance. We are dedicated to transforming the treatment landscape for autoimmune disease by developing innovative small molecules and protein-based therapeutics.

Our Pipeline

01

Redefining
Therapeutics

Leading the way with first in class small molecules and multi-specific protein drugs that target highly effective novel pathways.
02

Precision Targeting
for Maximum Impact

Unlocking new targets with cutting-edge small molecule innovation to maximize therapeutic potential.
03

A Distinctive
Therapeutic Platform

Expanding therapeutic strategies through our CR-Fc platform, enabling the development of tri-specific therapies.
04

Advanced
Pipelines

We are committed to rapidly advancing our robust pipeline to bring multiple programs into the clinic and transform the treatment of autoimmune diseases.

Our Approach

Advancing Precision
Immunotherapy

We are pioneering the discovery and development of small molecule drugs that selectively inhibit novel therapeutic targets implicated in autoimmune diseases. By suppressing inflammatory signaling and modulating Th17 immune responses, our compounds restore immune homeostasis and mitigate disease progression.

Targeting Immune
Dysregulation

In addition to small molecule therapeutics, we are advancing next-generation protein drugs designed to overcome the limitations of conventional biologics. Our proprietary platform enables the development of multi-targeting protein therapeutics, including dual and triple molecular target constructs, to enhance therapeutic efficacy. These novel biologics are engineered to minimize anti-drug antibody responses, ensuring prolonged treatment effectiveness and improved patient outcomes.